JP2023537904A5 - - Google Patents
Info
- Publication number
- JP2023537904A5 JP2023537904A5 JP2023507761A JP2023507761A JP2023537904A5 JP 2023537904 A5 JP2023537904 A5 JP 2023537904A5 JP 2023507761 A JP2023507761 A JP 2023507761A JP 2023507761 A JP2023507761 A JP 2023507761A JP 2023537904 A5 JP2023537904 A5 JP 2023537904A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- approximately
- day
- dose
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063852P | 2020-08-10 | 2020-08-10 | |
| US63/063,852 | 2020-08-10 | ||
| PCT/US2021/045443 WO2022035900A1 (en) | 2020-08-10 | 2021-08-10 | Gene therapies for neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537904A JP2023537904A (ja) | 2023-09-06 |
| JP2023537904A5 true JP2023537904A5 (https=) | 2024-08-21 |
Family
ID=77951788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507761A Pending JP2023537904A (ja) | 2020-08-10 | 2021-08-10 | 神経変性障害のための遺伝子療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346979A1 (https=) |
| EP (1) | EP4192517A1 (https=) |
| JP (1) | JP2023537904A (https=) |
| KR (1) | KR20230066360A (https=) |
| CN (1) | CN116437968A (https=) |
| AU (1) | AU2021325891A1 (https=) |
| CA (1) | CA3190864A1 (https=) |
| IL (1) | IL300409A (https=) |
| MX (1) | MX2023001564A (https=) |
| WO (1) | WO2022035900A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| CA3136004A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CN116672341A (zh) * | 2022-02-23 | 2023-09-01 | 中国科学院上海药物研究所 | 雷帕霉素在治疗渐冻症和额颞叶痴呆中的应用 |
| EP4598940A1 (en) | 2022-10-04 | 2025-08-13 | Eli Lilly and Company | Gene therapy for trem2-associated diseases and disorders |
| AU2023375569A1 (en) | 2022-11-11 | 2025-05-29 | Eli Lilly And Company | Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same |
| AU2023378899A1 (en) * | 2022-11-13 | 2025-06-26 | Alexion Pharma International Operations Limited | Gene therapy for frontotemporal dementia |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
| KR20250158063A (ko) * | 2023-03-16 | 2025-11-05 | 젠자임 코포레이션 | 건식 연령-관련 황반 변성의 치료 |
| WO2025251041A1 (en) * | 2024-05-31 | 2025-12-04 | Bluerock Therapeutics Lp | METHODS AND COMPOSITIONS FOR TREATING PROGRANULIN DEFICIENCIES USING iPSC-DERIVED CELLS |
| WO2026043765A1 (en) | 2024-08-21 | 2026-02-26 | Eli Lilly And Company | Engineered regulatory splice elements for gene therapies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008024998A2 (en) | 2006-08-24 | 2008-02-28 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
| EP3204503A1 (en) * | 2014-10-06 | 2017-08-16 | Arthrogen BV | Aav-based gene therapy |
| HK1256341A1 (zh) * | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| US20190328906A1 (en) * | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| JP7496667B2 (ja) | 2016-04-21 | 2024-06-07 | ビロベク，インコーポレイテッド | 昆虫細胞中でのａａｖ生成、方法およびその組成物 |
| IL316926A (en) * | 2017-05-11 | 2025-01-01 | Univ Pennsylvania | Gene therapy for neuronal ceroid lipofuscinosis |
| CA3068328A1 (en) * | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| AU2018346104B2 (en) | 2017-10-03 | 2023-07-27 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| BR112020006661A2 (pt) * | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| CA3136004A1 (en) * | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
-
2021
- 2021-08-10 AU AU2021325891A patent/AU2021325891A1/en active Pending
- 2021-08-10 MX MX2023001564A patent/MX2023001564A/es unknown
- 2021-08-10 US US18/041,199 patent/US20230346979A1/en active Pending
- 2021-08-10 WO PCT/US2021/045443 patent/WO2022035900A1/en not_active Ceased
- 2021-08-10 CA CA3190864A patent/CA3190864A1/en active Pending
- 2021-08-10 IL IL300409A patent/IL300409A/en unknown
- 2021-08-10 EP EP21778589.8A patent/EP4192517A1/en active Pending
- 2021-08-10 JP JP2023507761A patent/JP2023537904A/ja active Pending
- 2021-08-10 KR KR1020237008510A patent/KR20230066360A/ko active Pending
- 2021-08-10 CN CN202180068282.7A patent/CN116437968A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537904A5 (https=) | ||
| JP2023537903A5 (https=) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| US12440580B2 (en) | Adeno-associated virus vectors encoding modified G6PC and uses thereof | |
| JP2021522273A5 (https=) | ||
| JP2022526021A5 (https=) | ||
| US20040142416A1 (en) | Treatment for phenylketonuria | |
| JP2022523766A5 (https=) | ||
| JP2021533805A5 (https=) | ||
| JP2022526823A5 (https=) | ||
| CN117512014A (zh) | 酸性α-葡萄糖苷酶变体及其用途 | |
| JP2022520232A5 (https=) | ||
| JP2022531861A5 (https=) | ||
| WO2007120533A2 (en) | Minigene expression cassette | |
| JP2024545183A (ja) | ウイルスベクターによりｂａｇ－３関連心筋症を処置するための方法および組成物 | |
| JP2023503850A5 (https=) | ||
| US20240058477A1 (en) | Methods and compositions for treatment of friedreich's ataxia | |
| JP2023539247A (ja) | Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 | |
| JP2025138648A (ja) | Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| WO2019200286A1 (en) | Bicistronic aav vectors encoding hexosaminidase alpha and beta-subunits and uses thereof | |
| JP2025509828A (ja) | ウイルスベクターによるｔｎｎｔ２関連心筋症を処置するための方法および組成物 | |
| JP7693676B2 (ja) | ハンター病治療用のアデノ随伴ウイルスベクター | |
| JP2025509864A (ja) | ウイルスベクターによりｒｂｍ２０関連心筋症を処置するための方法および組成物 | |
| JP7674391B2 (ja) | グルコース－６－ホスファターゼ（Ｇ６Ｐａｓｅ－ａ）をコードする遺伝子治療用ベクター | |
| US20240207370A1 (en) | Gene therapy for bcaa modulation in maple syrup urine disease (msud) |